Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 305.31 USD 0.51% Market Closed
Market Cap: 39.8B USD

Wall Street
Price Targets

ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast ALNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALNY is 330.33 USD with a low forecast of 214.12 USD and a high forecast of 525 USD.

Lowest
Price Target
214.12 USD
30% Downside
Average
Price Target
330.33 USD
8% Upside
Highest
Price Target
525 USD
72% Upside
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
206650
EuBiologics Co Ltd
25% Upside
KRYS
Krystal Biotech Inc
59% Upside
EDIT
Editas Medicine Inc
89% Upside
AUPH
Aurinia Pharmaceuticals Inc
29% Upside
XGN
Exagen Inc
7% Upside
ARMP
Armata Pharmaceuticals Inc
365% Upside
068270
Celltrion Inc
42% Upside
005690
Pharmicell Co Ltd
41% Upside

Revenue
Forecast

Revenue Estimate
Alnylam Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 62%. The projected CAGR for the next 3 years is 29%.

62%
Past Growth
29%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALNY's stock price target?
Price Target
330.33 USD

According to Wall Street analysts, the average 1-year price target for ALNY is 330.33 USD with a low forecast of 214.12 USD and a high forecast of 525 USD.

What is Alnylam Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
29%

For the last 8 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 62%. The projected CAGR for the next 3 years is 29%.

Back to Top